Dr Reddy's Laboratories has received approval to manufacture and market generic semaglutide, a weight loss drug, once Novo Nordisk's patent expires in 2026.
The company is banking on key new launches, including weight loss drug Semaglutide and biosimilar Abatacept to drive growth ...
Britain's Medicines and Healthcare products Regulatory Agency seized a large cache of unlicensed weight-loss drugs, including ...
Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...
Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for ...
Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...
Many others in the industry also lamented the fact that an important route to generate alpha for investors has been closed by ...
Many others in the industry also lamented the fact that an important route to generate alpha for investors has been closed by ...
Why is the Supreme Court’s directive to notify a new Saranda wildlife sanctuary important for your UPSC exam? What ...
Capital Market on MSN
Cipla partners with Eli Lilly to distribute Tirzepatide in India under second brand Yurpeak
Mumbai, Oct. 24 -- "The introduction of a second brand of Tirzepatide in India through our commercial agreement with Cipla ...
Please provide the article or its content so I can generate an SEO-friendly meta description based on your guidelines.
22hon MSN
Eli Lilly, Incyte post new late-stage trial data for Olumiant in adolescents with hair loss
Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) are set to seek a label expansion for their JAK inhibitor baricitinib, marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback